La. Jury Hits J&J With $258M Verdict In Risperdal Suit

Law360, New York (October 15, 2010, 2:58 PM EDT) -- A Louisiana jury has smacked a Johnson & Johnson unit with a $257.7 million verdict in the state's suit against the company for downplaying the link between its antipsychotic drug Risperdal and diabetes.

The jury reached a verdict late Thursday in the 27th Judicial Court, St. Landry Parish, finding that J&J and its unit Janssen Pharmaceutica Inc. made misrepresentations in 2003 and 2004 about the drug's link to diabetes, according to Louisiana Attorney General James D. “Buddy” Caldwell.

“This verdict sends a loud message to those...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.